Climb Bio, Inc. (NASDAQ:CLYM) Receives $20.30 Consensus PT from Analysts

Climb Bio, Inc. (NASDAQ:CLYM) has been given a consensus recommendation of “Buy” by the thirteen analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and three have given a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $20.30.

Several equities analysts have weighed in on the stock. Chardan Capital assumed coverage on shares of Climb Bio in a research report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective on the stock. B. Riley Financial assumed coverage on shares of Climb Bio in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. Robert W. Baird set a $21.00 target price on shares of Climb Bio in a research report on Wednesday, May 6th. Finally, Wedbush lifted their target price on shares of Climb Bio from $15.00 to $17.00 and gave the company an “outperform” rating in a research note on Friday, May 8th.

Climb Bio Stock Performance

NASDAQ CLYM opened at $11.00 on Friday. Climb Bio has a twelve month low of $1.16 and a twelve month high of $12.48. The stock has a market cap of $629.86 million, a price-to-earnings ratio of -14.10 and a beta of 0.02. The firm’s 50 day moving average price is $8.70 and its two-hundred day moving average price is $5.73.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.06. On average, research analysts forecast that Climb Bio will post -0.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Climb Bio

A number of institutional investors have recently modified their holdings of CLYM. AQR Capital Management LLC acquired a new stake in shares of Climb Bio during the 1st quarter valued at $27,000. Goldman Sachs Group Inc. acquired a new stake in shares of Climb Bio during the 1st quarter valued at $147,000. Marshall Wace LLP acquired a new stake in shares of Climb Bio during the 2nd quarter valued at $46,000. Qube Research & Technologies Ltd acquired a new stake in shares of Climb Bio during the 2nd quarter valued at $43,000. Finally, Jane Street Group LLC acquired a new stake in shares of Climb Bio during the 2nd quarter valued at $184,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.